UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Burden of Illness for Osteoporotic Fractures Compared With Other Serious Diseases Among Postmenopausal Women in the United States

Mayo Clinic proceedings, 2015, Vol.90 (1), p.53-62

2015

Volltextzugriff (PDF)

Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis

PloS one, 2020-04, Vol.15 (4), p.e0229959-e0229959

2020

Volltextzugriff (PDF)

Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients

Nephrology, dialysis, transplantation, 2012-06, Vol.27 (6), p.2418-2425

2012

Volltextzugriff (PDF)

Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease

Current therapeutic research, 2023-01, Vol.98, p.100696-100696, Article 100696

2023

Volltextzugriff (PDF)

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Journal of Osteoporosis, 2015-01, Vol.2015, p.627631-9

2015

Volltextzugriff (PDF)

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

Hematology reports, 2018-05, Vol.10 (2), p.7643-7643

2018

Volltextzugriff (PDF)

Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease

JAMA network open, 2019-11, Vol.2 (11), p.e1915374-e1915374

2019

Volltextzugriff (PDF)

Patient-Reported Outcomes in Chronic Heart Failure

JACC. Heart failure, 2016-10, Vol.4 (10), p.791-804

2016

Volltextzugriff (PDF)

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers

Blood, 2021-11, Vol.138 (Supplement 1), p.3099-3099

2021

Volltextzugriff (PDF)

9: A Simplified Case-Mix Adjuster Model for the Proposed End Stage Renal Disease (ESRD) Prospective Payment System (PPS)

American journal of kidney diseases, 2010, Vol.55 (4), p.B34-B34

Agodoa, Irene

2010

Volltextzugriff (PDF)

10: Alternative Higher Predictive Model for the End Stage Renal Disease (ESRD) Prospective Payment System (PPS)

American journal of kidney diseases, 2010, Vol.55 (4), p.B34-B34

Agodoa, Irene

2010

Volltextzugriff (PDF)

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Blood, 2022-11, Vol.140 (Supplement 1), p.10833-10834

2022

Volltextzugriff (PDF)

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Blood, 2021-11, Vol.138 (Supplement 1), p.2052-2052

2021

Volltextzugriff (PDF)

Opioid utilization patterns in United States individuals with sickle cell disease

American journal of hematology, 2018-10, Vol.93 (10), p.E345-E347

2018

Volltextzugriff (PDF)

Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis

Expert review of hematology, 2022-02, Vol.15 (2), p.167-173

2022

Volltextzugriff (PDF)

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Blood, 2020-11, Vol.136 (Supplement 1), p.31-32

2020

Volltextzugriff (PDF)

The Role of Hemoglobin and Hemolysis on Transcranial Doppler Velocities in Children with Sickle Cell Disease: Data from a Natural History Cohort

Blood, 2021-11, Vol.138 (Supplement 1), p.3092-3092

2021

Volltextzugriff (PDF)

Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Estimated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis

Blood, 2018-11, Vol.132 (Supplement 1), p.12-12

2018

Volltextzugriff (PDF)

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Blood, 2019-11, Vol.134 (Supplement_1), p.2313-2313

2019

Volltextzugriff (PDF)

Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study

Blood, 2019-11, Vol.134 (Supplement_1), p.1002-1002

2019

Volltextzugriff (PDF)

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Blood, 2020-11, Vol.136 (Supplement 1), p.25-25

2020

Volltextzugriff (PDF)

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

Blood, 2020-11, Vol.136 (Supplement 1), p.27-28

2020

Volltextzugriff (PDF)

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Blood, 2020-11, Vol.136 (Supplement 1), p.19-19

2020

Volltextzugriff (PDF)

A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

Applied health economics and health policy, 2014-06, Vol.12 (3), p.267-277

2014

Volltextzugriff (PDF)

Quality of Care in United States Children with Sickle Cell Anemia

Blood, 2017-12, Vol.130, p.2098-2098

2017

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

ThemaChild

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(48)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Burden of Illness for Osteoporotic Fractures Compared With Other Serious Diseases Among Postmenopausal Women in the United States

Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis

Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients

Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease

Patient-Reported Outcomes in Chronic Heart Failure

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers

9: A Simplified Case-Mix Adjuster Model for the Proposed End Stage Renal Disease (ESRD) Prospective Payment System (PPS)

10: Alternative Higher Predictive Model for the End Stage Renal Disease (ESRD) Prospective Payment System (PPS)

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease

Opioid utilization patterns in United States individuals with sickle cell disease

Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

The Role of Hemoglobin and Hemolysis on Transcranial Doppler Velocities in Children with Sickle Cell Disease: Data from a Natural History Cohort

Low Hemoglobin Increases Risk for Stroke, Kidney Disease, Elevated Estimated Pulmonary Artery Systolic Pressure, and Premature Death in Sickle Cell Disease: A Systematic Literature Review and Meta-Analysis

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Transcranial Doppler Velocities Conversion Rate Based on Increasing Hemoglobin Concentration: Analysies from the SCCRIP Cohort Study

Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

The Impact of Hemoglobin Level on Risk of End-Organ Damage among Patients with Sickle Cell Disease - A Large-Scale, Longitudinal Analysis

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

Quality of Care in United States Children with Sickle Cell Anemia

Aktive Filter

Suchergebnisse filtern